Document Detail


Pharmacological interventions for treating heart failure in patients with chagas cardiomyopathy.
MedLine Citation:
PMID:  23152267     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chagas disease-related cardiomyopathy is a major cause of morbidity and mortality in Latin America. Despite the substantial burden to the healthcare system, there is uncertainty regarding the efficacy and safety of pharmacological interventions for treating heart failure in patients with Chagas disease.
OBJECTIVES: To assess the benefits and harms of current pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library) Issue 1, 2011, MEDLINE (Ovid), EMBASE (Ovid), LILACS and ISI Web of Science to April 2011. We checked the reference lists of included papers. No language restrictions were applied.
SELECTION CRITERIA: We included randomized clinical trials assessing the effects of pharmacological interventions for treating heart failure in adult patients (≥18 years) with symptomatic heart failure (New York Heart Association class II to IV), irrespective of the left ventricular ejection fraction stage, reduced or preserved, with Chagas cardiomyopathy. No limits were applied with respect to the follow-up duration. Primary outcomes were all-cause mortality, cardiovascular mortality at 30 days, time to heart decompensation and disease-free period (at 30, 60 and 90 days), and adverse events.
DATA COLLECTION AND ANALYSIS: Two authors independently performed study selection, risk of bias assessment and data extraction. We estimated relative risks (RR) and the respective 95% confidence intervals (CIs) for dichotomous outcomes. We measured statistical heterogeneity using the I(2) statistic. We used a fixed-effect model to synthesize the findings. We contacted authors for additional data.
MAIN RESULTS: We included two randomized clinical trials involving 69 participants. Both trials compared carvedilol against placebo, and had a high risk of bias. Carvedilol compared with placebo did not significantly affect all-cause mortality (2/34 (5.88%) versus 3/35 (5.87%); pooled RR 0.69, 95% CI 0.12 to 3.88, I(2) = 0%). None of the trials reported on cardiovascular mortality, time to heart decompensation or disease-free period. Evidence on the adverse effects of carvedilol is inconclusive.
AUTHORS' CONCLUSIONS: This Cochrane review has found a lack of evidence on the effects of carvedilol for treating heart failure in patients with Chagas disease. The two included trials were underpowered and had a high risk of bias. There are no conclusive data to support the use of carvedilol for treating Chagas cardiomyopathy. Unless randomized clinical trials provide evidence of a treatment effect, and the trade off between potential benefits and harms is established, policy-makers, clinicians, and academics should be cautious when recommending and administering carvedilol for treating heart failure in patients with Chagas disease. The efficacy and safety of other pharmacological interventions for treating heart failure in patients with Chagas disease is unknown.
Authors:
Ricardo Hidalgo; Arturo J Martí-Carvajal; Joey S W Kwong; Daniel Simancas-Racines; Susana Nicola
Related Documents :
7818317 - Deferoxamine cardioplegia reduces superoxide radical production in human myocardium.
12687197 - Redox regulation of neutrophils and monocytes in different types of myocardial infarction.
20025547 - Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative ...
1948967 - Are leukocytosis and lipid peroxidation involved in ischemic or reperfusion injury in c...
17209007 - Electroacupuncture decreases the susceptibility to ventricular tachycardia in conscious...
636847 - Brain monoamines in human cerebral infarcts. a preliminary study.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review     Date:  2012-11-14
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  11     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2012  
Date Detail:
Created Date:  2012-11-15     Completed Date:  2013-01-15     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD009077     Citation Subset:  IM    
Affiliation:
Facultad de Ciencias de la Salud Eugenio Espejo, Universidad Tecnológica Equinoccial, Quito, Ecuador.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Carbazoles / adverse effects,  therapeutic use*
Cardiotonic Agents / adverse effects,  therapeutic use*
Chagas Cardiomyopathy / complications*
Heart Failure / drug therapy*,  etiology
Humans
Propanolamines / adverse effects,  therapeutic use*
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
0/Carbazoles; 0/Cardiotonic Agents; 0/Propanolamines; 0K47UL67F2/carvedilol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Psychological therapies for pathological and problem gambling.
Next Document:  Antibiotics for uncomplicated diverticulitis.